Author(s): Goda JS, LeLW, Lapperriere NJ, Millar BA, Payne D, et al.
Methods and materials:From 1989 to 2007, 89 patients with Stage IE POML received RT. The median age was 56 years old. Sites involved conjunctiva (59 patients [66%]), lacrimal gland (20 patients [23%]), and soft tissue (10 patients [11%]). Megavoltage beam(s) was used in 91%, electrons in 7%, and orthovoltage in 2% of cases. The dose given was 25 Gy in 97% and 30 Gy in 3% of patients. Lens shielding was possible in 57% of patients.
Results:The median follow-up was 5.9 years. Complete response or unconfirmed complete response was seen in 88 patients (99%). Relapse occurred in 22 patients (25%). First relapse sites were local (2 patients [9%]), in the contralateral orbit (5 patients [23%]), and distant (15 patients [68%]). The 7-year overall survival (OS), cause-specific survival (CSS), relapse-free survival (RFS), and local control (LC) rates were 91%, 96%, 64%, and 97%, respectively. Radiation-related late sequelae were documented in 40 patients (45%). Cataracts were observed in 22 patients (Grade 1 in 2 patients; Grade 3 in 20 patients). The incidence of Grade 3 cataract at 7 years was 25%. Other late sequelae (n = 28) were dry eye(s) (22 patients [Grade 1 in 14 patients; Grade 2 in 2 patients; Grade 3 in 2 patients; n/s in 4 patients), keratitis (3 patients), macular degeneration/cystoid edema (2 patients), and vitreous detachment (1 patient). Five patients developed Grade 3 noncataract late effects. Lens shielding reduced the incidence of Grade 3 cataract and all Grade ≥2 late sequelae. Seventeen patients (16 with cataracts) underwent surgery; 23 patients were treated conservatively. The outcome for managing late effects was generally successful, with 30 patients completely improved, and 9 patients with persisting late sequelae (10%).
Conclusions:POML responds favorably to moderate doses of RT but results in significant late morbidity. The majority of late effects were successfully managed. Lens shielding reduced the risk of cataracts and other late sequelae.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/21640514
Author(s): Jaffe ES, Harris NL, Stein H, Vardiman JW
Author(s): Fitzpatrick PJ, Macko S
Author(s): Margo CE, Mulla ZD
Author(s): Fung CY, Tarbell NJ, Lucarelli MJ, Goldberg SI, Linggood RM, et al.
Author(s): Dunbar SF, Linggood RM, Doppke KP
Author(s): Esik O, Ikeda H, Mukai K
Author(s): Smitt MC, Donaldson SS
Author(s): Stafford SL, Kozelsky TF, Garrity JA
Author(s): Lee SW, Suh CO, Kim GE
Author(s): Lee JL, Kim MK, Lee KH, Hyun MS, Chung HS, et al.
Author(s): Deeg HJ, Flournoy N, Sullivan KM
Author(s): Henk JM, Whitelocke RA, Warrington AP
Author(s): Suh CO, Shim SJ, Lee SW
Author(s): Uno T, Isobe K, Shikama N
Author(s): Le QT, Eulau SM, George TI
Author(s): Tsang RW, Gospodarowicz MK, Pintilie M
Author(s): Husain A, Roberts D, Pro B, McLaughlin P, Esmaeli B